Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$798M |
| 2 |
Netflix
NFLX
|
+$608M |
| 3 |
UnitedHealth
UNH
|
+$517M |
| 4 |
Apple
AAPL
|
+$461M |
| 5 |
GE Vernova
GEV
|
+$296M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$527M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$372M |
| 3 |
Meta Platforms (Facebook)
META
|
+$362M |
| 4 |
Advanced Micro Devices
AMD
|
+$328M |
| 5 |
Palantir
PLTR
|
+$327M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Healthcare | 15.79% |
| 3 | Consumer Discretionary | 12.36% |
| 4 | Financials | 11.53% |
| 5 | Industrials | 8.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1651
Portillo's
PTLO
$339M
| $4.05M | 0.01% |
347,441
+310,344
| +837% | +$3.58M |
2024 Q4
2 quarters
|
|
1652
YieldMax MSTR Option Income Strategy ETF
MSTY
$1.07B
| $4.05M | 0.01% |
+36,560
| New | +$4.01M |
2025 Q2
0 quarters
|
|
1653
State Street SPDR S&P Biotech ETF
XBI
$9.75B
| $4.05M | 0.01% |
+48,800
| New | +$3.89M |
2025 Q2
0 quarters
|
|
1654
Sensient Technologies
SXT
$5.68B
| $4.04M | 0.01% |
41,048
+15,548
| +61% | +$1.39M |
2025 Q1
1 quarter
|
|
1655
Vanguard FTSE All-World ex-US Small-Cap Index Fund
VSS
$11.5B
| $4.03M | 0.01% |
30,000
+11,100
| +59% | +$1.37M |
2025 Q1
1 quarter
|
|
1656
First Trust Rising Dividend Achievers ETF
RDVY
$25.4B
| $4.03M | 0.01% |
+64,200
| New | +$3.78M |
2025 Q2
0 quarters
|
|
1657
Aspen Aerogels
ASPN
$449M
| $4.02M | 0.01% |
679,200
-84,900
| -11% | -$488K |
2024 Q2
4 quarters
|
|
1658
First Trust NASDAQ Cybersecurity ETF
CIBR
$18.7B
| $4.02M | 0.01% |
+53,200
| New | +$3.65M |
2025 Q2
0 quarters
|
|
1659
Mereo BioPharma
MREO
$49.5M
| $4.01M | 0.01% |
1,480,471
+130,000
| +10% | +$314K |
2020 Q2
20 quarters
|
|
1660
El Pollo Loco
LOCO
$485M
| $4M | 0.01% |
363,000
+14,200
| +4% | +$141K |
2017 Q2
32 quarters
|
|
1661
Autolus Therapeutics
AUTL
$426M
| $3.99M | 0.01% |
1,751,200
+167,075
| +11% | +$276K |
2022 Q2
12 quarters
|
|
1662
Vanguard Morningstar Mega Cap Growth ETF
MGK
$35.4B
| $3.99M | 0.01% |
+54,500
| New | +$3.59M |
2025 Q2
0 quarters
|
|
1663
KRONOS Worldwide
KRO
$854M
| $3.98M | 0.01% |
641,532
-120,900
| -16% | -$829K |
2016 Q1
37 quarters
|
|
1664
Gran Tierra Energy
GTE
$375M
| $3.96M | 0.01% |
829,580
+29,300
| +4% | +$139K |
2021 Q2
16 quarters
|
|
1665
Mueller Water Products
MWA
$3.41B
| $3.95M | 0.01% |
164,400
-130,100
| -44% | -$3.22M |
2023 Q3
7 quarters
|
|
1666
Alkami Technology
ALKT
$1.5B
| $3.95M | 0.01% |
130,900
-272,100
| -68% | -$7.56M |
2024 Q1
5 quarters
|
|
1667
York Water
YORW
$506M
| $3.94M | 0.01% |
124,536
+28,100
| +29% | +$938K |
2013 Q2
48 quarters
|
|
1668
DELISTED
Steelcase
SCS
| $3.93M | 0.01% |
376,800
+78,300
| +26% | +$806K |
2023 Q4
6 quarters
|
|
1669
Here Group Ltd
HERE
$88.6M
| $3.93M | 0.01% |
415,700
+378,700
| +1,024% | +$2.64M |
2024 Q2
4 quarters
|
|
1670
CSP Inc
CSPI
$74.2M
| $3.93M | 0.01% |
303,526
-700
| -0.2% | -$10.1K |
2013 Q2
48 quarters
|
|
1671
DELISTED
TrueCar
TRUE
| $3.93M | 0.01% |
2,066,601
-6,300
| -0.3% | -$9.62K |
2019 Q1
25 quarters
|
|
1672
Dorian LPG
LPG
$2.48B
| $3.92M | 0.01% |
160,972
+143,672
| +830% | +$3.18M |
2025 Q1
1 quarter
|
|
1673
Northeast Community Bancorp
NECB
$382M
| $3.92M | 0.01% |
168,800
-16,000
| -9% | -$362K |
2021 Q3
15 quarters
|
|
1674
DELISTED
ZimVie
ZIMV
| $3.91M | 0.01% |
418,500
+58,500
| +16% | +$534K |
2022 Q2
12 quarters
|
|
1675
Invesco KBW Bank ETF
KBWB
$6.21B
| $3.91M | 0.01% |
+54,600
| New | +$3.46M |
2025 Q2
0 quarters
|
|
Similar funds
Renaissance Technologies's Q2 2025 Portfolio in Review
As of Q2 2025, Renaissance Technologies held 4,018 positions worth $75.2B, up 14% from $66.1B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Renaissance Technologies's Q2 2025 filing shows 612 new, 1,577 increased, 1,314 reduced and 496 closed positions. Its largest new stake was UnitedHealth: 1,352,129 shares worth $422M. The largest sale was Broadcom, an estimated $527M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 17% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Renaissance Technologies's largest Q2 2025 buy was UnitedHealth: 1,352,129 shares worth $422M.
- Renaissance Technologies added most to NVIDIA in Q2 2025, an estimated $798M increase.
- Renaissance Technologies's biggest Q2 2025 reduction was Broadcom, cutting an estimated $527M.
- Renaissance Technologies fully exited Advanced Micro Devices in Q2 2025, selling an estimated $328M.
- Renaissance Technologies's ten largest holdings make up 12% of its $75.2B portfolio in Q2 2025.
- Renaissance Technologies opened 612 new positions and closed 496 in Q2 2025.
- Renaissance Technologies's portfolio value rose 14% quarter-over-quarter to $75.2B.
Based on Renaissance Technologies's 13F filing for Q2 2025, filed 13 Aug 2025.